ArticleVeterinary research2026
An efficient and versatile reverse genetics system for bovine coronavirus facilitates antiviral evaluation.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bovine coronavirus (BCoV), a primary etiological agent of calf diarrhea, exhibits dual tropism for the respiratory and enteric tracts. However, research on BCoV gene function and pathogenesis has been limited by the lack of convenient and flexible reverse genetics tools. Herein, we report a robust reverse genetics system for BCoV based on an optimized circular polymerase extension reaction (CPER) methodology. We successfully rescued recombinant BCoV (rBCoV) in HRT-18G cells and engineered recombinant BCoV expressing ZsGreen fluorescent protein (rBCoV/Zs-T2A-ns2). Phenotypic analysis demonstrated that both unmodified rBCoV and rBCoV/Zs-T2A-ns2 maintained growth kinetics comparable to the wild-type BCoV. Importantly, the reporter virus demonstrated remarkable genetic stability for over ten passages, identifying the ns2 locus as a suitable insertion site for stable foreign gene expression without compromising viral fitness or sequence integrity. As a proof-of-concept application, the rBCoV/Zs-T2A-ns2 was employed for antiviral compound evaluation, successfully identifying four compounds-camostat, nafamostat, niclosamide, and nelfinavir-capable of effectively inhibiting BCoV replication. Further time-of-addition assays revealed that nelfinavir and niclosamide targeted the BCoV replication stage, while camostat and nafamostat interfered with BCoV internalization. This versatile CPER-based reverse genetics system provides a critical platform for advanced BCoV pathogenesis research and accelerated development of novel vaccines and effective antiviral therapeutics, ultimately contributing to enhanced bovine health and sustainable livestock production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.